newsfilter
← Latest News
GlobeNewswire·

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and